Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models

Chien Tai Hong, Kai Yin Chau, Anthony H V Schapira

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.

Original languageEnglish
Article number25344
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - May 5 2016

Fingerprint

Meclizine
Glycolysis
Parkinson Disease
Phosphofructokinase-2
Histamine Agents
Phosphofructokinases
Aptitude
Oxidopamine
Huntington Disease
Fructose
Cell Death
Stroke
Apoptosis
Enzymes

ASJC Scopus subject areas

  • General

Cite this

Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. / Hong, Chien Tai; Chau, Kai Yin; Schapira, Anthony H V.

In: Scientific Reports, Vol. 6, 25344, 05.05.2016.

Research output: Contribution to journalArticle

@article{0dd6fb8005544817bed5f15d0f03b98a,
title = "Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models",
abstract = "Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.",
author = "Hong, {Chien Tai} and Chau, {Kai Yin} and Schapira, {Anthony H V}",
year = "2016",
month = "5",
day = "5",
doi = "10.1038/srep25344",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models

AU - Hong, Chien Tai

AU - Chau, Kai Yin

AU - Schapira, Anthony H V

PY - 2016/5/5

Y1 - 2016/5/5

N2 - Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.

AB - Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.

UR - http://www.scopus.com/inward/record.url?scp=84966365384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966365384&partnerID=8YFLogxK

U2 - 10.1038/srep25344

DO - 10.1038/srep25344

M3 - Article

AN - SCOPUS:84966365384

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 25344

ER -